AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

AI Summary

AbbVie is reportedly close to acquiring Apogee Therapeutics in an $11 billion deal focused on inflammatory disease drugs. Regenxbio has progressed gene therapy approval steps with the FDA, while SpaceX shares continue to decline post-IPO.

On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO. (Source: Bloomberg)